Antibody-Drug Conjugate Cuts Death Risk by 54% in Relapsed Small-Cell Lung Cancer
The phase III TAISHAN-302 trial found that the anti-B7-H3 antibody-drug conjugate Tam-Peli reduced the risk of death by 54 percent ...
Tag: YL201
POPULAR NEWS
-
Jamun fruit concentrate shows promise as natural beef marinade in lab study
-
Antibody-Drug Conjugate Cuts Death Risk by 54% in Relapsed Small-Cell Lung Cancer
-
Explainable AI yields a five-parameter formula for nonlinear concrete creep
-
Reuse quality of open polymer datasets: a reproducible cross-repository audit (2020–2025)